Home  »  News   »  Analysts Mean recommendation for ImmunityBio Inc. ...

Analysts Mean recommendation for ImmunityBio Inc. (IBRX) was 2.00: Is this the key time?

For the readers interested in the stock health of ImmunityBio Inc. (IBRX). It is currently valued at $5.51. When the transactions were called off in the previous session, Stock hit the highs of $5.94, after setting-off with the price of $5.85. Company’s stock value dipped to $5.11 during the trading on the day. When the trading was stopped its value was $6.06.Recently in News on July 28, 2022, ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ. This acceptance represents the first regulatory filing for N-803, an IL-15 superagonist, which was granted Breakthrough Therapy and Fast Track designations in combination with Bacillus Calmette-Guérin (BCG) from the U.S. Food and Drug Administration (FDA) for this indication with a target PDUFA date of May 23, 2023. You can read further details here

ImmunityBio Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $7.85 on 02/17/22, with the lowest value was $2.60 for the same time period, recorded on 05/12/22.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


ImmunityBio Inc. (IBRX) full year performance was -45.87%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, ImmunityBio Inc. shares are logging -49.35% during the 52-week period from high price, and 111.92% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.60 and $10.88.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3054878 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the ImmunityBio Inc. (IBRX) recorded performance in the market was -9.37%, having the revenues showcasing 73.82% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.34B, as it employees total of 740 workers.

Analysts verdict on ImmunityBio Inc. (IBRX)

During the last month, 0 analysts gave the ImmunityBio Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 4.10, with a change in the price was noted +1.73. In a similar fashion, ImmunityBio Inc. posted a movement of +45.57% for the period of last 100 days, recording 1,912,753 in trading volumes.

ImmunityBio Inc. (IBRX): Technical Analysis

Raw Stochastic average of ImmunityBio Inc. in the period of last 50 days is set at 46.50%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 44.15%. In the last 20 days, the company’s Stochastic %K was 56.10% and its Stochastic %D was recorded 71.94%.

Let’s take a glance in the erstwhile performances of ImmunityBio Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -9.37%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -6.93%, alongside a downfall of -45.87% for the period of the last 12 months. The shares increased approximately by -1.78% in the 7-day charts and went down by 26.96% in the period of the last 30 days. Common stock shares were driven by 73.82% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts